Analyst Ratings for Neumora Therapeutics (NMRA)
NMRA Rating Summary
NMRA Price Target Summary
- Highest: $14.00 (Guggenheim)
- Lowest: $3.00 (Stifel)
- Average: $7.14
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$7.14 (+373%)
* Over Last 12-Mos
Rating Score: 6.4 / 10
Percentile Rank: 67%
Avg. $ Target:
$7.14 (+373%)
* Over Last 12-Mos
Rating Score: 6.4 / 10
Percentile Rank: 67%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/17/2026 | William Blair | Myles R. Minter | Upgrade | Outperform (Market Perform) |
N/A (N/A) |
3.20 (1.51) |
-52.81% | Details |
| 1/12/2026 | Leerink | Marc Goodman | New Coverage | Outperform (N/A) |
8.00 (N/A) |
2.33 (1.51) |
-35.19% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
